Focus: Dyne Therapeutics is a public biotech company specializing in antibody-oligonucleotide conjugate treatments for rare muscle diseases, operating at mid-cap scale (~300 employees) from Waltham, MA.
Profile data last refreshed 17h ago · AI intelligence enriched 1mo ago
Cooling — net -13 jobs in 30d
39 added, 52 removed. Slower than typical.
Best suited for early-stage biotech specialists seeking differentiated science and commercial upside, but unsuitable for those prioritizing near-term revenue stability or established product expertise.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Dyne Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Dyne Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
At $16 a share, director Brian S. Posner buys 2,500 Dyne Therapeutics (DYN) shares. - Stock Titan
At $16 a share, director Brian S. Posner buys 2,500 Dyne Therapeutics (DYN) shares. Stock Titan
Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF) and Dyne Therapeutics (DYN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF) and Dyne Therapeutics (DYN) The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF) and Dyne Therapeutics (DYN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF) and Dyne Therapeutics (DYN) The Globe and Mail
Dyne Therapeutics stock rises on positive DM1 trial results - Yahoo! Finance Canada
Dyne Therapeutics stock rises on positive DM1 trial results Yahoo! Finance Canada
Dyne Therapeutics Announces Additional One-Year Clinical - GlobeNewswire
Dyne Therapeutics Announces Additional One-Year Clinical GlobeNewswire
Piper Sandler reiterates Dyne Therapeutics stock rating on drug approval confidence - Investing.com
Piper Sandler reiterates Dyne Therapeutics stock rating on drug approval confidence Investing.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo